NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis $3.85 -0.09 (-2.28%) Closing price 04:00 PM EasternExtended Trading$4.09 +0.24 (+6.23%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About CNS Pharmaceuticals Stock (NASDAQ:CNSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CNS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.77▼$3.9850-Day Range$3.94▼$6.0152-Week Range$1.90▼$10.54Volume5,795 shsAverage Volume432,228 shsMarket Capitalization$5.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for primary and metastatic cancers of the central nervous system. The company is headquartered in Houston, Texas, and its shares trade on the Nasdaq Capital Market under the symbol CNSP. CNS Pharmaceuticals’ lead product candidate is berubicin, an anthracycline designed to cross the blood-brain barrier. The company is evaluating berubicin as a potential treatment for glioblastoma multiforme, an aggressive and often fatal form of brain cancer for which treatment options remain limited. Berubicin has been studied in clinical trials involving patients with recurrent glioblastoma. The company’s development activities are centered on advancing berubicin through clinical development and evaluating its potential in other central nervous system malignancies. Its clinical research has included patients in the United States and selected European countries. John M. Climaco serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More CNS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCNSP MarketRank™: 0.34008485014 of 5 starsCNS Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCNS Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CNS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCNS Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CNS Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently increased by 44.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.82% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by Institutions14.02% of the stock of CNS Pharmaceuticals is held by institutions.Read more about CNS Pharmaceuticals' insider trading history. Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSP Stock News HeadlinesCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationAugust 12, 2026 | finanznachrichten.deCNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor PresentationJune 9, 2026 | markets.businessinsider.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)CNS Pharmaceuticals (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic TransformationMay 15, 2026 | theglobeandmail.comForget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6May 14, 2026 | 247wallst.comWhat's going on with CNS Pharmaceuticals stock on Wednesday?May 6, 2026 | msn.comCNS Pharmaceuticals Announces Private Placement and Board ChangesMay 6, 2026 | theglobeandmail.comWhy did CNSP stock surge 330% today?May 5, 2026 | msn.comSee More Headlines CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed this year? CNS Pharmaceuticals' stock was trading at $5.25 at the beginning of 2026. Since then, CNSP stock has decreased by 22.7% and is now trading at $4.06. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) issued its earnings results on Wednesday, August, 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.14. When did CNS Pharmaceuticals' stock split? Shares of CNS Pharmaceuticals reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $10 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,125,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NIO (NIO), Palantir Technologies (PLTR), Plug Power (PLUG), Intel (INTC), NVIDIA (NVDA), Novavax (NVAX) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2026Today11/10/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, CNSP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CNSP CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees8Year Founded2017Profitability EPS (Trailing Twelve Months)($23.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-204.25% Return on Assets-141.87% Debt Debt-to-Equity RatioN/A Current Ratio5.86 Quick Ratio5.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.29 per share Price / Book0.55Miscellaneous Outstanding Shares1,460,000Free Float1,434,000Market Cap$5.87 million OptionableNot Optionable Beta3.21 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CNSP) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIt’s now or neverAnthropic's Claude now generates more revenue than ChatGPT, and the company is about to go public at a $1.5 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
